Clinical trials: Pulmonary Aspergillosis
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Invasive Pulmonary Aspergillosis
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.
- Trial name
- SCYNERGIA (NCT03672292)
- Testing
- SCY-078, Voriconazole
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 22 people
- Sponsor
- Scynexis, Inc.
Allergic Bronchopulmonary Aspergillosis (ABPA)
Interest of IgE Directed Against Recombinant Antigens of Aspergillus Fumigatus in the Diagnosis of Allergic Bronchopulmonary Aspergillosis (ABPA)
Allergic Bronchopulmonary Aspergillosis is a rare pulmonary disease involving allergic mechanisms, which historically affects patients with asthma or cystic fibrosis only. It is a source of respiratory decompensation.
- Trial name
- BPCO (NCT07055230)
- Where
- France
- Volunteers
- 67 people
- Sponsor
- University Hospital, Rouen
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.
- Trial name
- NCT01222273
- Testing
- cholecalciferol (Vitamin D3)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pittsburgh
COVID-19 Respiratory Infection, Aspergillosis
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 associated pulmonary aspergillosis (CAPA) is considered a potentially life-threatening infection in critically ill COVID (Corona Virus disease)-19 patients.
- Trial name
- POSACOVID (NCT05065658)
- Testing
- Posaconazole
- Where
- 3 sites in Austria, France and 1 more
- Volunteers
- 249 people
- Sponsor
- Medical University of Graz
Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD)
Immune Status and Disease Control of Inflammatory Airway Diseases
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand: 1.Whether specific immune cell patterns in the blood are linked…
- Conditions
- Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis
- Trial name
- ISDC-IAD (NCT07493629)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
Aspergillosis; Pulmonary, Invasive (Etiology)
Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
The objective of this study is to deliver proof of concept that antifungal prophylaxis can reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit) patients with severe influenza.
- Trial name
- POSA-FLU (NCT03378479)
- Testing
- SOC +Posaconazole 18 MG/ML (milligram/milliliter), standard of care (SOC)
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 88 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Invasive Aspergillosis
Application of an Electronic Nose in the Early Detection of ASpergillosis
The purpose of this study is to establish the accuracy with which the eNose can discriminate patients with invasive pulmonary aspergillosis from controls.
- Trial name
- AENEAS (NCT01395446)
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ABPA, Severe Asthma
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis
- Trial name
- NCT04108962
- Testing
- Fasenra, 30 Mg/mL Subcutaneous Solution
- Where
- United States
- Sponsor
- Baylor Research Institute
Influenza With Pneumonia, Pulmonary Aspergillosis
Prospective Observational Trial of IAPA
A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU…
- Trial name
- IAPAFLU (NCT04530799)
- Testing
- Identification of biomarkers for IAPA via patient sampling
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 241 people
- Sponsor
- Radboud University Medical Center
Obstructive Pulmonary Disease
Physiotherapy Treatment Plan in Allergic Bronchopulmonary Aspergillosis: Case Report
A spirometry study is performed in a patient diagnosed with allergic bronchopulmonary aspergillosis. An initial measurement is carried out and the patient is then put on a four-week physiotherapy treatment plan.
- Trial name
- NCT04748900
- Testing
- spirometer
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Universidad Católica de Ávila
Invasive Pulmonary Aspergillosis, Breath Samples
VOC in Breath Samples for the Diagnosis of IPA
The diagnosis of invasive pulmonary aspergillosis (IPA) bears grave implications for the prognosis and treatment plan of the immunosuppressed patient.
- Conditions
- Invasive Pulmonary Aspergillosis, Breath Samples, Volatile Organic Compounds
- Trial name
- NCT05982912
- Testing
- breath sampling
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Invasive Fungal Disease, Lung Transplant Recipients
Assessing Diagnostic Methods for Invasive Fungal Disease in Lung Transplant Recipients
This study aims to assess the diagnostic performance of different tests, including metagenomic next-generation sequencing (mNGS), real-time PCR, galactomannan assay, and lateral-flow device tests, in detecting invasive fungal…
- Conditions
- Invasive Fungal Disease, Lung Transplant Recipients, Invasive Pulmonary Aspergillosis, Pneumocystis Jirovecii Pneumonia
- Trial name
- NCT06654076
- Volunteers
- 109 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Allergic Bronchopulmonary Aspergillosis
Deflazacort Vs. Prednisolone in Acute-stage ABPA
Oral glucocorticoids are currently the treatment of choice for allergic bronchopulmonary aspergillosis (ABPA). They not only suppress the immune hyperfunction but are also anti-inflammatory.
- Trial name
- NCT04227483
- Testing
- Deflazacort, Prednisolone
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the…
- Conditions
- Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
- Trial name
- MIRAGE (NCT06244979)
- Testing
- Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Invasive Pulmonary Aspergillosis
Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)
The investigators aim to assess the safety and efficacy of nebulized liposomal amphotericin B (ALN) as a complementary therapy to the usual systemic treatment in patients with invasive pulmonary aspergillosis and the utility of a…
- Trial name
- NAIFI01 (NCT04267497)
- Testing
- Amphotericin B Liposomal 50 MG
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Invasive Pulmonary Aspergillosis
Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study
Background Invasive pulmonary aspergillosis (IPA) remains an important cause of morbidity and mortality among patients with hemato-oncological malignancies.
- Trial name
- NCT02058316
- Testing
- Lateral Flow Device Test
- Where
- 4 sites in Austria, Germany
- Volunteers
- 350 people
- Sponsor
- Medical University of Graz
Aspergillosis
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945
- Trial name
- NCT02715570
- Testing
- PC945 - single doses, PC945 - repeat doses
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pulmocide Ltd
Invasive Aspergillosis, Pleural Effusion
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Diagnostic accuracy of biomarker testing (galactomannan (GM), (1
- Conditions
- Invasive Aspergillosis, Pleural Effusion, Immunosuppression
- Trial name
- EFFU-ASP (NCT02104479)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Heidelberg University
Fungal Infection Lungs
Risk of Aspergillus Infection in Patients With Chronic Lung Disease
Large doses of systemic corticosteroids ，severe lung tissue damage and longer COPD diagnosis may increase the risk of IPA in patients with chronic structural lung disease.
- Trial name
- NCT06379568
- Testing
- No intervention
- Where
- China
- Volunteers
- 209 people
- Sponsor
- Lin Chen